Knight Therapeutics Investor Relations Material

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Impavido (miltefosine), an oral antifungal product for the treatment of visceral, cutaneous, and mucosal leishmaniasis; Macrilen (macimorelin), a growth hormone secretagogue receptor agonist for use in the investigational stimulation testing of adults with adult growth hormone deficiency; Probuphine (buprenorphine) implant for subdermal administration to facilitate remission from opioid use disorder; Neuragen or NeurogesX topical research portfolio consisting of Qutenza (capsaicin 8% patch) for neuropathic pain indication in Canada.